RLRayhan Adi Lal

Rayhan Adi Lal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Recognitions

Top Cited Young Scholar (2026)
Top Cited Scholar (2026)

Rayhan Adi Lal has a total of 551 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effects of Menstrual Cycle on Insulin Sensitivity in Type 1 Diabetes: An Observational Study of Individuals Using an Automated Insulin Delivery System

    by Stefanie Hossmann, Maya Friedman, Aritz Lizoain, Madleina Caduff, Vincent Braunack-Mayer, Laura Burlando, Rayhan A. Lal, Eda Cengiz, Katarina Braune, Susanne Reger-Tan, et al.

    OBJECTIVE: In menstruating individuals with type 1 diabetes, hormonal fluctuations across the menstrual cycle may alter insulin sensitivity and glycemia, despite advances in automated insulin delivery (AID) systems. This study aimed to characterize glycemic patterns, insulin requirements, and insulin sensitivity across menstrual cycle phases. RESEARCH DESIGN AND METHODS: We conducted a decentralized, observational study using real-world data donated by menstruating adults reporting regular menstrual cycles and using an AID system. Participants self-enrolled and contributed anonymized continuous glucose monitoring (CGM), insulin delivery, carbohydrate intake, and menstrual cycle data. Glycemic outcomes and insulin requirements were compared across cycle phases. Cycle phase–specific variation in insulin sensitivity was quantified using a hierarchical Bayesian state-space model that estimates a latent insulin sensitivity parameter from CGM time series data. RESULTS: Seventy-seven individuals contributed 380 menstrual cycles. Insulin requirements, carbohydrate intake, and glycemic outcomes showed systematic variation across cycle phases. Total daily insulin dose and carbohydrate intake peaked during the luteal phase, accompanied by higher mean glucose and reduced time in range. At the population level, model-derived estimates indicated greater insulin sensitivity (+2.6%, credible interval [CrI] 0.3, 5.0) in the early follicular compared with the midluteal phase (−2.6%, CrI −5.2, −0.1). Although 84.7% of participants showed patterns consistent with the population-level trend, substantial interindividual heterogeneity was observed. CONCLUSIONS: Our findings confirm phase-dependent variation in insulin needs, glycemic outcomes, and insulin sensitivity across the menstrual cycle and highlight that sex-specific physiology is an important factor in glycemic regulation that is not yet addressed by current guidelines and AID systems.


  • Open Access

    Continuous Intraperitoneal Insulin Infusion for People With Type 1 Diabetes: A Literature Review and International Position Statement

    by Nick Oliver, Bernhard Gehr, Rayhan Lal, Peter R. van Dijk, Eric Renard

    Achieving glucose targets without hypoglycaemia is the treatment goal in type 1 diabetes. Structured education, intensified insulin injection regimens, continuous glucose monitoring, automated insulin delivery, and ongoing support from a multidisciplinary team all support people with type 1 diabetes to achieve this goal. Despite these advances, significant barriers to achieving optimal management remain. Continuous intraperitoneal insulin infusion has comparable or better glucose outcomes to continuous subcutaneous insulin infusion and may reduce the frequency of hypoglycaemia, including severe episodes. Intraperitoneal insulin may be considered as a treatment modality for children and adults with type 1 diabetes using optimised intensive insulin therapy for whom subcutaneous insulin has failed due to lipoatrophy, ‐dystrophy or ‐hypertrophy, local allergy, subcutaneous insulin resistance or co‐existing skin conditions. Failure of subcutaneous insulin may result in recurrent or unexplained severe hypoglycaemia or hyperglycaemia. Intraperitoneal insulin may also be considered as a treatment modality for people with type 1 diabetes with severe needle‐phobia, and for those being considered for islet cell or pancreatic transplantation, or where transplantation is not available. This paper summarises current intraperitoneal insulin delivery technology, its potential risks and benefits, and an expert position statement. It is intended for use by diabetes specialist healthcare professionals, and as a reference for other healthcare professionals, commissioners, payors, people with diabetes, their carers, and advocates.


  • Open Access

    Data Processing and Best Practices in Large-Scale Diabetes Datasets

    by Dana M. Lewis, Ahtsham Zafar, Abiodun Solanke, Dessi P. Zaharieva, Rayhan Lal, Rachel Guo, Arsalan Shahid

    Background: Data analysis plays a pivotal role in transforming raw data into findings that are transparent, reproducible, and clinically meaningful and useful, which is critical when analyzing insulin-related data for diabetes studies. Failing to do so will make subsequent analysis of insulin data irrelevant due to inaccuracies. Objective: Describe the end-to-end pre-processing steps used for assessing the T1DEXI dataset and why these steps are necessary before moving to data analysis. Methods: Standardize and harmonize the raw datasets, including comparing devices and adjusting per-device pre-processing steps; mitigating gaps in data; accounting for extended insulin delivery that is articulated as single timestamp records as well as similarly accounting for suspension of insulin delivery, taking into account the periods of time in which insulin was or was not delivered. Results: Insulin-related data is transformed to uniform per-5-minute intervals and is able to be used for subsequent analysis and event-based interpretation. Conclusions: As it relates to insulin delivery, pre-processing should be used to make sure that insulin delivery is uniformly analyzed down to 5-minute intervals so that all insulin delivery event types, whether those be manual up-front boluses; basal or temporary basal rates; and extended bolus events (such as square or dual/square wave boluses) and suspend events are correctly documented as a timeseries such that subsequent analysis will be accurate based on the duration of insulin activity.

  • Swimming With the Omnipod 5 Automated Insulin Delivery System: An Observational Investigation of Swimmers With Type 1 Diabetes in the Omnipod 5 Pivotal Trial

    by Dessi P. Zaharieva, Ryan S. Kingman, Rayhan A. Lal, Ed Nykaza, Bruce A. Buckingham, Michael S. Hughes

    Aims: Limited studies have investigated glucose management around swimming in type 1 diabetes (T1D). This observational study of the Omnipod 5 Automated Insulin Delivery (AID) System assessed glycemic patterns and system operation with AID use during swimming. Materials and Methods: A total of seven swimmers (aged 11 ± 2 years, 57% female) with T1D recorded their swims using an activity tracker and completed online surveys after swims. Results: Participants reported 124 swims lasting 23–146 min. Median (IQR) starting glucose was 133 (93–178) mg/dL, with a change of −17 (−61 to 7) mg/dL during swims. Carbohydrate intake 2‐h before swims was 20 (0–32) grams. Starting glucose ≥ 181 mg/dL showed the largest glucose decreases [−86 (−111 to −25) mg/dL] during swims. Activity feature was used in 87% of swims with a starting glucose < 90 mg/dL. Automated Mode was maintained for 98% (95%–100%) of swim time with 58% (24%–70%) of this time in Automated Mode: Limited. Conclusions: Swimming with AID was associated with generally modest declines in glucose. The Omnipod 5 System largely preserved automation in water (often via Automated Mode: Limited) without reverting to Manual Mode. Starting glucose dominated glycemic trajectory, with larger declines but low hypoglycemia risk at a higher starting glucose, and smaller changes, but more hypoglycemia at a lower starting glucose. Insulin suspension was not enough to reliably prevent hypoglycemia when starting glucose was < 180 mg/dL, highlighting the need for proactive carbohydrate intake with a lower starting glucose, even with AID.


  • Open Access

    Comparison of Glucose Management Between Open‐Source Loop and Tandem Control‐ IQ Automated Insulin Delivery Systems in Adults With Type 1 Diabetes

    by Zekai Wu, Maha Lebbar, Rayhan Lal, Anne Bonhoure, Virginie Messier, Élisabeth Nguyen, Valérie Boudreau, Anne‐Sophie Brazeau, Rémi Rabasa‐Lhoret

  • Open Access

    Integrating the Glycemia Risk Index Into Clinical Practice and Research: A Consensus Report

    by Guillermo E. Umpierrez, Viral N. Shah, Veronica Brady, Mark A. Clements, Juan Espinoza, Elizabeth Healey, Michael A. Kohn, David M. Maahs, Ralph Oiknine, Jane J. Seley, et al.

    A panel of experts in the use of continuous glucose monitoring (CGM) data in the treatment of diabetes met in Burlingame, California on October 27, 2025 to discuss the utility of the glycemia risk index (GRI) for clinical care research and population health management. The GRI composite metric is a single number (on a 0-100 percentile scale—lower is better) based on an expert-determined weighting of the seven individual components in the existing ambulatory glucose profile (AGP). The GRI describes the quality of glycemia based on glucose values collected in a 14-day CGM tracing, thus providing additional insights into CGM profiles beyond the AGP. During the meeting, the mathematical derivation of the GRI metric was presented along with its use for adult and pediatric individuals with diabetes and cancer who require medications that can adversely affect the glucose concentration. Examples where the GRI provided useful insights into the quality of CGM tracings were also discussed by the expert panel. In addition, a new smartphone application, the GRI Calculator, was presented. This app calculates the GRI of a CGM tracing and provides visualization of sequential CGM tracings for a specific individual. The GRI provides a reference measurement for the accuracy of artificial intelligence (AI) models assigning levels of glycemic quality to CGM tracings intended to match the assessments of clinicians. The GRI is now part of the data visualization panel for the Integration of Connected Diabetes Device Data into the Electronic Health Record (iCoDE-2) project, which standardizes both CGM and insulin dosing data. Further exploration of the potential value of the GRI for non-insulin users needs to be undertaken. The panel unanimously recommended that CGM manufacturers and developers of data visualization software for CGMs add the GRI to their data platforms for insulin users.


  • Open Access

    Fully closed-loop systems: can people with type 1 diabetes just do it? Insights from open-source systems

    by Rayhan Lal, Katarina Braune, Dana M. Lewis, Lenka Petruzelkova, Martin de Bock, Sufyan Hussain

    Automated insulin delivery (AID) systems have significantly advanced diabetes management, progressively reducing user interactions required for optimal glucose management. This review evaluates the current landscape and future potential of AID systems without meal announcement, particularly focusing on real-world insights from open-source AID (OS-AID) technologies. Although commercial AID systems operating in hybrid closed-loop (HCL) mode have improved glycaemic outcomes, they remain dependent on manual meal announcement and user-driven actions, limiting their real-world utility. Current versions of OS-AID systems, developed by the diabetes community, can allow operation without meal announcements, presenting an opportunity to move closer to truly automated diabetes management. Recent clinical trials suggest that OS-AID systems can effectively manage glucose levels without meal announcements, achieving glucose levels comparable with those obtained by AID systems in HCL mode, with the potential of reduced management burden for users. However, practical challenges persist, including the need for expert configuration and handling of rapid changes in insulin sensitivity, such as during exercise or rapid glucose fluctuations following predicted low-glucose. This review synthesises insights from user and healthcare professional experiences, and emerging clinical evidence. It highlights the fact that successful implementation of AID without meal announcement requires advanced algorithmic responsiveness, user personalisation and ongoing clinician engagement. Looking forward, integrating adjunctive therapies, artificial intelligence and enhanced physiological modelling will likely enhance system performance to drive the next generation of diabetes care towards wider adoption and true ‘set-and-forget’ functionality. Graphical Abstract


  • Psychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel‐group clinical trial sub‐study

    by Jean‐Pierre Riveline, Eric Renard, Grazia Aleppo, Bruce W. Bode, Sue A. Brown, Kristin Castorino, Irl B. Hirsch, Mark S. Kipnes, Lori M. Laffel, Rayhan A. Lal, et al.

    Aims: Beyond their glycaemic benefits, automated insulin delivery (AID) systems can provide psychosocial benefits for people with type 1 diabetes (T1D) and improve quality of life. In this study, we evaluated psychosocial outcomes in adults with T1D using the tubeless Omnipod® 5 AID System compared with sensor augmented pump (SAP) therapy. Materials and Methods: As part of a 13‐week multicentre, parallel‐group, randomised controlled trial comparing intervention (tubeless AID) and control (SAP) groups (2:1), adults aged 18–70 years with T1D completed validated psychosocial questionnaires assessing health‐related quality of life (European Quality of Life 5 Dimensions 3 Level Version [EQ‐5D‐3L] index score and visual analogue scale [VAS]), the impact of diabetes on quality of life (DAWN2 Impact of Diabetes Profile [DIDP]), sleep quality (Pittsburgh Sleep Quality Index [PSQI]), system usability (System Usability Scale [SUS]) and perceptions before and experiences after using AID systems (INsulin Dosing Systems: Perceptions, Ideas, Reflections and Expectations [INSPIRE]). Results: The intervention group saw greater score improvements than the control group for all measures evaluated, including health‐related quality of life (EQ‐5D‐3L VAS, p = 0.01; EQ‐5D‐3L index score, p = 0.002), impact of diabetes on quality of life (DIDP, p = 0.004), perceived system usability (SUS, p < 0.0001) and sleep quality (PSQI, p = 0.03). INSPIRE scores, determined only for the intervention group, were high at baseline and follow‐up, suggesting positive perceptions of tubeless AID. Conclusions: This randomised controlled trial demonstrated that the use of a tubeless AID system improved psychosocial measures to a greater extent than SAP therapy. These results contribute to the growing body of evidence demonstrating that AID may improve quality of life and alleviate some of the burden associated with diabetes self‐management in adults with T1D.


  • Open Access

    Safety and Glycemic Outcomes of the MiniMed 780G System with a Disposable All-in-One Sensor

    by Laura M. Nally, Jennifer L. Sherr, Satish K. Garg, Brynn E. Marks, Lori M. Laffel, Catherine Pihoker, Siham D. Accacha, James R. Thrasher, M. Jennifer Abuzzahab, John H. Reed, et al.

    Introduction: The present study assessed the impact of the disposable Simplera Sync™ sensor with the MiniMed™ 780G (MM780G) advanced hybrid closed-loop (AHCL) system on type 1 diabetes (T1D) glycemic metrics, insulin delivery, and safety. Materials and Methods: Youths (aged 7–17 years) and adults (aged 18–80 years) with T1D were enrolled in this single-arm, nonrandomized study at 24 sites in the United States. Participants began with an ∼2-week run-in period where hybrid closed-loop (HCL; auto basal only) or open-loop insulin delivery was used, followed by an ∼3-month study period with AHCL activated. Glycemic outcomes and insulin delivery during the last 6–7 weeks of the study, when settings were optimized at investigator’s discretion, were compared with the run-in. Glycemic outcomes with the use of recommended optimal settings (ROS, 100 mg/dL glucose target with a 2-h active insulin time) were explored. Results: Time in automation was high (>93%) and mean time in range (TIR) increased from 54.4% ± 15.7% to 71.4% ± 9.9% ( P < 0.001) in youths and from 66.5% ± 12.6% to 80.2% ± 8.1% ( P < 0.001) in adults, primarily due to reduced time above range. Youths had a slight increase in time below range (TBR P < 0.001), while adults had no significant difference in TBR. For ROS users, TIR was 74.7% ± 9.3% in youths and 83.8% ± 7.4% in adults. Throughout the study ∼60% of total daily insulin dose was automated (auto basal and auto correction) in both cohorts. There were two cases of severe hypoglycemia and one episode of diabetic ketoacidosis (not related to the device). Conclusions: MM780G use with the Simplera Sync sensor is safe and demonstrated improved glycemic outcomes in both pediatric and adult participants with T1D, compared with the run-in period.